Beta Bionics, Inc. officer Stephen Feider filed a Form 144 notice of proposed sale of 744 shares of common stock, with an approximate sale date of November 9, 2026, through Merrill Lynch.

Key Highlights

  • Proposed sale: Stephen Feider, an officer of Beta Bionics, Inc., intends to sell 744 shares of common stock with an aggregate market value of $12,649.
  • Acquisition source: The 744 shares were acquired on November 9, 2026, via stock options from the issuer, with payment made in cash.
  • Shares outstanding: According to the filing, 54,367,067 shares of Beta Bionics common stock were outstanding at the time of notice.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of July 31, 2026.
  • Prior sales in past 3 months: Feider sold 382 shares on November 5, 2026, for gross proceeds of $6,508, and 6,675 shares on September 2, 2026, for gross proceeds of $129,595.13.
  • Broker: The proposed sale is to be executed through Merrill Lynch, located in Rancho Santa Fe, California.

Beta Bionics Officer Files Proposed Sale Notice Under Rule 144

Stephen Feider, identified in the filing as an officer of Beta Bionics, Inc. (NASDAQ:BBNX), submitted a Form 144 to the U.S. Securities and Exchange Commission on November 9, 2026. The notice covers a proposed sale of 744 shares of Beta Bionics common stock, with an aggregate market value of $12,649, to be executed through Merrill Lynch. The approximate date of sale listed in the filing is November 9, 2026.

According to the filing, the 744 shares subject to this notice were acquired on November 9, 2026, through stock options granted by the issuer, with cash listed as the nature of payment. The filing discloses that 54,367,067 shares of Beta Bionics common stock were outstanding at the time the notice was submitted. Feider also indicated that the proposed sale is being conducted pursuant to a Rule 10b5-1 trading plan adopted on July 31, 2026.

The filing further discloses Feider's sales of Beta Bionics common stock during the three months preceding the notice. Those prior transactions include the sale of 382 shares on November 5, 2026, generating gross proceeds of $6,508, and the sale of 6,675 shares on September 2, 2026, generating gross proceeds of $129,595.13. Beta Bionics, Inc. is headquartered at 11 Hughes, Irvine, California 92618, according to the filing.

What Was Disclosed

Stephen Feider, an officer at Beta Bionics, Inc., filed a Form 144 notice disclosing a proposed sale of 744 common shares with an aggregate market value of $12,649, acquired via stock options, to be sold through Merrill Lynch on or around November 9, 2026, under a 10b5-1 plan.